Special K, the pharmaceutical Holy Grail
What if there were a drug that not only reduced the risk of heart disease, but also protected
Wednesday, 27 March 2013
Vitamin K2 and bone health: new study demonstrates the importance of high vitamin K2 intake.
VitaK is happy to announce that on March 23, the first part of a 3-year clinical trial on vitamin K2 hasRead more...
Friday, 15 March 2013
VitaK receives grant for innovative skin project
VitaK has received an OP-ZUID grant for performance of an innovative skin project entitled: development of a toolbox for evaluation ofRead more...
Tuesday, 04 December 2012
Dr. Elke Theuwissen has been appointed as Vice-President R&D within VitaK BV
We are happy to announce that as per December 1, 2012 Dr. Elke Theuwissen has been appointed as Vice-President R&D withinRead more...
Thursday, 01 November 2012
Poor vitamin K status in kidney transplant patients
Poor vitamin K status is a well recognized risk for vascular calcification. A particular group at high risk for vascular calcification is formedRead more...
Wednesday, 12 September 2012
VitaK in the scientific press
In September 2012 a paper originating from VitaK was published in the British Journal of Nutrition. The authors address the question whether the bone-derived vitaminRead more...